Study finds potential new drug therapy for Crohn's disease

October 17, 2012

Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn's Disease, according to researchers at the University of California San Diego, School of Medicine. The study will appear in the October 18, 2012 issue of the New England Journal of Medicine (NEJM).

Results from the clinical trial showed ustekinumab (Stelara) increased and remission in suffering from moderate-to-severe Crohn's Disease - a form of (IBD) that can lead to a variety of , including diarrhea, intestinal bleeding and weight loss. Serious complications such as and abscesses can also occur.

"Our biggest challenge in treating patients with Crohn's Disease is managing patients whose bodies are resistant to (TNF) inhibitors such as Remicade, Humira and Cimzia," said Sanborn, MD, principal investigator and chief of the Division of Gastroenterology at the UC San Diego School of Medicine. "Ustekinumab blocks two proteins that cause inflammation, interleukin 12 and 23. This finding is a significant first step towards a new treatment option for these patients."

One third of patients with moderate-to-severe Crohn's Disease do not respond to current treatment with TNF inhibitors, which regulates the body's immune system and inflammation. Another one third of patients only have a temporary response.

Five hundred and twenty six patients were part of the randomized trial, which was conducted in 12 countries. Eligible patients were at least 18 years of age and had a confirmed diagnosis of Crohn's Disease for at least three months.

The patients were treated for 36 weeks in the placebo-controlled study. They were given an intravenous dose of ustekinumab at the beginning of the study and a subcutaneous dose every eight weeks. Benefits could be seen as early as six weeks of therapy.

Among patients treated, serious infection was reported in five patients and a basal-cell carcinoma, a form of skin cancer, was reported in one patient.

"These promising initial results are now being followed up and confirmed with additional Phase 3 induction trials – UNITI-1 (http://clinicaltrials.gov/ct2/show/NCT01369329?term=STELARA+Crohn%27s+disease&rank=3)and UNITI-2 (http://clinicaltrials.gov/ct2/show/NCT01369342?term=STELARA+Crohn%27s+disease&rank=2). A Phase 3 maintenance trial (IM-UNITI) http://clinicaltrials.gov/ct2/show/NCT01369355?term=STELARA+Crohn%27s+disease&rank=1) will also be conducted in which the patients who respond to ustekinumab will receive additional treatment for one year," said Sandborn, director of the Inflammatory Bowel Disease Center at UC San Diego Health System. "Our goal is to increase clinical response and put the disease in remission to improve the patient's quality of life."

Explore further: Study identifies potential new class of drug for treating ulcerative colitis

Related Stories

Study identifies potential new class of drug for treating ulcerative colitis

August 15, 2012
An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University ...

Adalimumab is a promising therapy for children with Crohn's disease

August 6, 2012
Adalimumab (an anti-tumor necrosis factor [TNF] antibody) is effective in maintaining remission in certain pediatric patients with Crohn's disease, according to a new study in Gastroenterology, the official journal of the ...

Use of naltrexone reduces inflammation in Crohn's patients

May 19, 2011
Naltrexone reduced inflammation in Crohn's patients in a research study at Penn State College of Medicine.

Recommended for you

Will these two home remedies help your sore throat?

December 18, 2017
(HealthDay)—Down go another two worthless home remedies for strep throat.

Simple tool may expedite transplants in kids with kidney failure

December 18, 2017
An easy-to-use tool to predict the likelihood of a child with kidney disease progressing to kidney failure has a high degree of accuracy and could be used to reduce the burden of dialysis and increase transplantations, according ...

New cellular approach found to control progression of chronic kidney disease

December 15, 2017
Researchers have demonstrated for the first time that extracellular vesicles - tiny protein-filled structures - isolated from amniotic fluid stem cells (AFSCs) can be used to effectively slow the progression of kidney damage ...

Testing shows differences in efficacy of Zika vaccines after one year

December 15, 2017
(Medical Xpress)—A large team of researchers with members from Harvard Medical School, Walter Reed Army Institute of Research, Bioqual Inc. and MIT has found that the efficacy of the three types of Zika vaccines currently ...

How to regulate fecal microbiota transplants

December 15, 2017
(Medical Xpress)—A small team of researchers at the University of Maryland, some with affiliations to the Veterans Affairs Maryland Health Care System, has written and published a Policy Forum piece in the journal Science ...

Screening could catch a quarter of hip fractures before they happen

December 15, 2017
Community screening for osteoporosis could prevent more than a quarter of hip fractures in older women - according to new research led by the University of East Anglia (UEA).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.